A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)

The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000002952

Enrollment

Unknown

Registered

2020-02-01

Start date

2020-02-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Group 1:TCM syndrome differentiation treatment+ Western medicine treatment

Group 2:Western medicine treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients with 2019-nCoV pneumonia; 2. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients complicated with active tuberculosis, malignant arrhythmia, acute myocardial infarction and stroke; 2. pregnant and lactating women; 3. Patients complicated with severe cognitive and mental disorders; 4. Clinical investigators who are participating in other interventions within one month prior to enrollment; 5. Those who are known to be allergic to therapeutic drugs.

Design outcomes

Primary

Measure	Time frame
Duration of PCR normalization;Clinical symptom score;	—

Secondary

Measure	Time frame
Hospitalization time;Arterial blood gas;pneumonia severity index, PSI;SF-36;Chest imaging;28-day prognosis;84-day prognosis;EQ-5D;	—

Countries

China

Contacts

Public ContactLi Jiansheng, Li Suyun

The First Hospital of He'nan University of Chinese Medicine

lisuyun2000@126.com+86 371 66248624

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026